Current research indicates that C5aR1 is the primary proinflammatory receptor, whereas C5aR2 appears to be an anti-inflammatory receptor.17 C5a inhibitors demonstrate unique therapeutic advantages in the prevention and treatment of sepsis through their precise immunomodulatory effects. The gene discussed is C5; the disease is Sepsis.